78 related articles for article (PubMed ID: 19015436)
1. Sunitinib and periodic hair depigmentation due to temporary c-KIT inhibition.
Hartmann JT; Kanz L
Arch Dermatol; 2008 Nov; 144(11):1525-6. PubMed ID: 19015436
[No Abstract] [Full Text] [Related]
2. Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans.
Moss KG; Toner GC; Cherrington JM; Mendel DB; Laird AD
J Pharmacol Exp Ther; 2003 Nov; 307(2):476-80. PubMed ID: 12966161
[TBL] [Abstract][Full Text] [Related]
3. [Memory resides in the hair].
Füeßl HS
MMW Fortschr Med; 2015 May; 157(10):36. PubMed ID: 26019089
[No Abstract] [Full Text] [Related]
4. Skin depigmentation induced by sunitinib treatment of renal cell carcinoma.
Al Enazi MM; Kadry R; Mitwali H
J Am Acad Dermatol; 2009 Nov; 61(5):905-6. PubMed ID: 19836653
[No Abstract] [Full Text] [Related]
5. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184.
Mackay HJ; Tinker A; Winquist E; Thomas G; Swenerton K; Oza A; Sederias J; Ivy P; Eisenhauer EA
Gynecol Oncol; 2010 Feb; 116(2):163-7. PubMed ID: 19740535
[TBL] [Abstract][Full Text] [Related]
6. [Metastatic apocrine adenocarcinoma of the penis: cytostatic therapy].
van Essen J; Heidenreich A
Aktuelle Urol; 2012 May; 43(3):177-9. PubMed ID: 22639028
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.
Machiels JP; Henry S; Zanetta S; Kaminsky MC; Michoux N; Rommel D; Schmitz S; Bompas E; Dillies AF; Faivre S; Moxhon A; Duprez T; Guigay J
J Clin Oncol; 2010 Jan; 28(1):21-8. PubMed ID: 19917865
[TBL] [Abstract][Full Text] [Related]
8. Reversible hair depigmentation in a patient treated with imatinib.
Mariani S; Abruzzese E; Basciani S; Fiore D; Persichetti A; Watanabe M; Spera G; Gnessi L
Leuk Res; 2011 Jun; 35(6):e64-6. PubMed ID: 21176848
[No Abstract] [Full Text] [Related]
9. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
Shen L
Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
[No Abstract] [Full Text] [Related]
10. Hair depigmentation during chemotherapy with dasatinib, a dual Bcr-Abl/Src family tyrosine kinase inhibitor.
Sun A; Akin RS; Cobos E; Smith J
J Drugs Dermatol; 2009 Apr; 8(4):395-8. PubMed ID: 19363859
[TBL] [Abstract][Full Text] [Related]
11. Evidence for PDGFRA, PDGFRB and KIT deregulation in an NSCLC patient.
Negri T; Casieri P; Miselli F; Orsenigo M; Piacenza C; Stacchiotti S; Bidoli P; Casali PG; Pierotti MA; Tamborini E; Pilotti S
Br J Cancer; 2007 Jan; 96(1):180-1. PubMed ID: 17213828
[No Abstract] [Full Text] [Related]
12. Images in clinical medicine. Sunitinib-associated hair depigmentation.
Brzezniak C; Szabo E
N Engl J Med; 2014 Apr; 370(17):e27. PubMed ID: 24758639
[No Abstract] [Full Text] [Related]
13. Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis.
Suwattee P; Chow S; Berg BC; Warshaw EM
Arch Dermatol; 2008 Jan; 144(1):123-5. PubMed ID: 18209189
[No Abstract] [Full Text] [Related]
14. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
Janeway KA; Albritton KH; Van Den Abbeele AD; D'Amato GZ; Pedrazzoli P; Siena S; Picus J; Butrynski JE; Schlemmer M; Heinrich MC; Demetri GD
Pediatr Blood Cancer; 2009 Jul; 52(7):767-71. PubMed ID: 19326424
[TBL] [Abstract][Full Text] [Related]
15. Rapid hair depigmentation in patient treated with pazopanib.
Šeparović R; Pavlović M; Silovski T; Tečić Vuger A
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30139781
[TBL] [Abstract][Full Text] [Related]
16. Hair depigmentation during chemotherapy with a class III/V receptor tyrosine kinase inhibitor.
Routhouska S; Gilliam AC; Mirmirani P
Arch Dermatol; 2006 Nov; 142(11):1477-9. PubMed ID: 17116839
[TBL] [Abstract][Full Text] [Related]
17. [Consensus on the medical treatment of gastrointestinal stromal tumors].
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
[No Abstract] [Full Text] [Related]
18. Hair discoloration caused by etretinate.
Nanda A; Alsaleh QA
Dermatology; 1994; 188(2):172. PubMed ID: 8136552
[No Abstract] [Full Text] [Related]
19. [Adverse effects of the tyrosine-kinase inhibitor sunitinib, a new drug for the treatment of advanced renal-cell cancer].
van der Veldt AA; van den Eertwegh AJ; Boven E
Ned Tijdschr Geneeskd; 2007 May; 151(20):1142-7. PubMed ID: 17557672
[TBL] [Abstract][Full Text] [Related]
20. Case 2. Hemangioblastomas: diagnosis of von Hippel-Lindau disease and antiangiogenic treatment with SU5416.
Schuch G; de Wit M; Höltje J; Laack E; Schilling G; Hossfeld DK; Fiedler W; Scigalla P; Jacobs MS
J Clin Oncol; 2005 May; 23(15):3624-6. PubMed ID: 15908674
[No Abstract] [Full Text] [Related]
[Next] [New Search]
